Prot #EFC17599: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 3-Arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older with Mode

Project: Research project

Project Details

StatusActive
Effective start/end date11/12/2411/12/27

Funding

  • ICON Clinical Research, LLC (Prot #EFC17599 // Prot #EFC17599)
  • Sanofi US Services Inc. (Prot #EFC17599 // Prot #EFC17599)